So what is MOTS-c? It's a tiny peptide scientists found in 2015, tucked inside a gene they'd already been reading for years. Search it today and you'll get long lists of what it does in people. Most readers assume someone tested those claims by giving MOTS-c to people and publishing the results. Nobody has. Not yet.
What is MOTS-c? A natural signal, studied mostly in mice
MOTS-c is a peptide, a short chain of protein building blocks, 16 of them long. Its code sits in mitochondrial DNA, the small, separate set of genes inside the cell's power plants. The body makes it on its own. That's exactly why the research is so easy to misread. You can measure the body's own MOTS-c in a blood sample without anyone adding a drop.
The proof: measured isn't the same as given
Let's get into it.
It was hiding in plain sight. In 2015, a team at the University of Southern California found a short stretch of code inside a mitochondrial gene called 12S rRNA, a gene already known for a different job. It reads out a 16-building-block peptide, and the name is basically its address: mitochondrial open reading frame of the 12S rRNA, type c. Picture finding a note folded inside a book everyone had already read. In cells and mice, it ended up switching on AMPK, an enzyme that works like the cell's fuel gauge (Lee et al., Cell Metab 2015).
The most quoted human result is a measurement. In 2021, the USC group and colleagues in New Zealand sampled blood and muscle from ten sedentary young men before, during and after a ride on a stationary bike. MOTS-c in their blood rose about one and a half times, then drifted back to baseline within four hours (Reynolds et al., Nat Commun 2021). That's the body's own MOTS-c, measured. Nobody was given any.
Same paper, different species. So where was MOTS-c actually given? Mice, timed on a treadmill and a spinning rod. One paper, two kinds of evidence, split cleanly by species. Headlines tend to glue them back together.
So why should you care? Because "MOTS-c does X in people" usually traces back to that glue. In its July 2026 review, the FDA said it had found no clinical studies or human exposure data for MOTS-c (FDA briefing, 2026). The first placebo-controlled trial that gives it to people started in February 2026 and hasn't reported results (ClinicalTrials.gov). On our A to E evidence ladder, that's a D.
"But didn't an FDA panel vote for it?" It did, 7 to 5 with 2 abstentions on July 23, 2026, over the objections of FDA staff (AJMC, July 2026). That was advice about the pharmacy compounding list, not an approval. As of October 2026 the FDA hasn't acted on it.
And the vial? Here's one thing you can check on paper. PubChem lists MOTS-c at a molecular weight of 2,174.6 (PubChem). The LC-MS identity result on the certificate should match that weight. If it doesn't, it isn't MOTS-c, whatever the label says.
The big learning lesson
Keep reading: MOTS-c vs SS-31, compared side by side · Why mitochondria matter, and the peptides studied with them · What actually happened with the FDA "peptide ban" in 2026
Frequently asked questions
What is MOTS-c?
It's a 16-amino-acid peptide coded in mitochondrial DNA, first described by a University of Southern California team in 2015. It's studied as a signal mitochondria send to the rest of the cell, mostly in cells and mice.
Where does MOTS-c come from?
Its code sits inside a mitochondrial gene called 12S rRNA, and the body makes it naturally. Research material is made synthetically with the same 16-building-block sequence.
Is MOTS-c FDA approved?
No. An FDA advisory committee recommended it for the pharmacy compounding list in July 2026, but that's non-binding advice, not an approval. The first placebo-controlled trial giving it to people hasn't reported results.